RxDoctor Payments Data

Jennifer Porta, DO

Hematology & Oncology · Springdale, ARNPI 1699209478

Payments from drug & device makers

$1,735in general payments, 2019–2025

Across 96 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$238
  • Stemline Therapeutics Inc.$175
  • Puma Biotechnology, Inc.$161
  • Novartis$110
  • Johnson & Johnson$92
  • Bristol Myers Squibb$84
  • plus $875 from 24 others

What the payments were for

  • Food & beverage$1,68497%
  • Education$513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,735 in reported general payments places this provider in the 30th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$3,901,233
Medicare patients
1,194
Services billed
201,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib17$255,641
JakafiRuxolitinib Phosphate11$189,924
EliquisApixaban24$15,783
XareltoRivaroxaban15$9,043
Anastrozole238$3,507
Prochlorperazine Maleate38$1,469
Letrozole62$1,067
Ondansetron OdtOndansetron72$797
Hydroxyurea23$515
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$363
Dexamethasone30$337
Lidocaine-PrilocaineLidocaine/Prilocaine29$327
Fluconazole11$281
Warfarin Sodium48$245
Olanzapine14$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio, Olanzapine$16$255,87931 claims
Incyte CorporationJakafi$35$189,92411 claims
PfizerEliquis$52$15,78324 claims
Johnson & JohnsonXarelto$92$9,04315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →